JThe following companies are expected to report earnings before the market opens on 05/16/2022. See our results calendar for a full list of expected results releases.

Tower Semiconductor Ltd. (TSEM) reports for the quarter ending March 31, 2022. The power company’s consensus earnings-per-share forecast from the top analyst tracking the stock is $0.47. This value represents an increase of 74.07% compared to the same quarter last year. In the past year, TSEM met analysts’ expectations twice and exceeded expectations the other two quarters. Zacks Investment Research reports that the 2022 price-to-earnings ratio for TSEM is 23.69 versus an industry ratio of 8.00, implying that they will have higher earnings growth than their competitors in the same industry.

Wix.com Ltd. (WIX) releases a report for the quarter ending March 31, 2022. The information technology services company’s consensus earnings per share forecast from the 6 analysts who track the stock is -$1.75. This value represents a decrease of 28.68% compared to the same quarter last year. Over the past year, WIX has met analysts’ expectations once and exceeded them the other three quarters. Zacks Investment Research reports that the 2022 P/E ratio for WIX is -11.48 versus an industry ratio of 35.50.

Sohu.com Limited (SOHU) reports for the quarter ending March 31, 2022. The internet services company’s consensus earnings-per-share forecast from the top analyst tracking the stock is -$0.31. This value represents a decrease of 138.75% compared to the same quarter last year. Over the past year, SOHU has exceeded expectations every quarter. The highest was in the 4th calendar quarter where they beat the consensus of 114.75%. Zacks Investment Research reports that the 2022 price-to-earnings ratio for SOHU is -8.48 versus an industry ratio of 2.10.

Chimerix, Inc. (CMRX) reports for the quarter ending March 31, 2022. The medical products company’s consensus earnings-per-share forecast from the 4 analysts who track the stock is -$0.35. This value represents a decrease of 94.44% compared to the same quarter last year. Zacks Investment Research reports that the 2022 P/E ratio for CMRX is -27.33 versus an industry ratio of -9.20.

Gracell Biotechnologies Inc. (GRCL) reports for the quarter ending March 31, 2022. The consensus earnings per share forecast for the biomedical company (gene) from the 2 analysts who track the stock is -$0.08. This value represents an increase of 68.00% compared to the same quarter last year. Days to cover, as reported in the brief interest update on 04/29/2022, has increased by 160.00% compared to the previous report on 04/14/2022. Zacks Investment Research reports that the 2022 P/E ratio for GRCL is -8.72 versus an industry ratio of -1.10.

Luna Innovations Incorporated (LUNA) releases a report for the quarter ending March 31, 2022. The technology services company’s consensus earnings per share forecast from the 2 analysts who track the stock is -$0.03. This value represents a decrease of 400.00% compared to the same quarter last year. Zacks Investment Research reports that the 2022 price-to-earnings ratio for LUNA is 37.00 versus an industry ratio of 6.00, implying that they will have higher earnings growth than their competitors in the same industry.

Compugen Ltd. (CGEN) releases its report for the quarter ending March 31, 2022. The consensus earnings per share forecast for the biomedical company (gene) from the 5 analysts who track the stock is -$0.12. This value represents a no change for the same quarter last year. In the past year, CGEN has met analysts’ expectations once and exceeded them the other three quarters. Zacks Investment Research reports that the 2022 P/E ratio for CGEN is -3.62 versus an industry ratio of -1.10.

Impel Pharmaceuticals Inc. (IMPL) reports for the quarter ending March 31, 2022. The pharmaceutical company’s consensus earnings-per-share forecast from the top analyst tracking the stock is -$1.08. This value represents a decrease of 100.00% compared to the same quarter last year. Zacks Investment Research reports that the 2022 P/E ratio for IMPL is -1.61 versus an industry ratio of 0.80.

Alaunos Therapeutics, Inc. (TCRT) reports for the quarter ending March 31, 2022. The pharmaceutical company’s consensus earnings-per-share forecast from the 3 analysts who track the stock is -$0.09. This value represents an increase of 10.00% compared to the same quarter last year. Over the past year, TCRT has exceeded expectations every quarter. The highest was in the 4th calendar quarter where they beat consensus by 44.44%. The “days to cover” for this stock exceeds 13 days. Zacks Investment Research reports that the 2022 P/E ratio for TCRT is -1.82 versus an industry ratio of 0.80.

Taysha Gene Therapies, Inc. (TSHA) reports for the quarter ending March 31, 2022. The medical company’s consensus earnings-per-share forecast from the 6 analysts who track the stock is -$1.03. This value represents a decrease of 18.39% compared to the same quarter last year. Zacks Investment Research reports that the 2022 P/E ratio for TSHA is -0.82 versus an industry ratio of 2.80.

Brainstorming Cell Therapeutics Inc. (BCLI) reports for the quarter ending March 31, 2022. The consensus earnings per share forecast for the biomedical company (gene) from the 1 analyst tracking the stock is -$0.13. This value represents an increase of 31.58% compared to the same quarter last year. Over the past year, BCLI has exceeded expectations every quarter. The highest was in the 4th calendar quarter where they beat consensus by 15%. The “days to cover” for this stock exceeds 13 days. Zacks Investment Research reports that the 2022 P/E ratio for BCLI is -4.52 versus an industry ratio of -1.10.

Passage Bio, Inc. (PASG) reports for the quarter ending March 31, 2022. The consensus earnings per share forecast for the biomedical company (gene) from the 4 analysts who track the stock is -$0.88. This value represents a decrease of 15.79% compared to the same quarter last year. Zacks Investment Research reports that the 2022 price-to-earnings ratio for PASG is -0.50 versus an industry ratio of -1.10, implying that they will have higher earnings growth than their competitors in the same industry.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.